人工病历审查揭示非典型股骨骨折患者双膦酸盐暴露误分类:两个国际队列的病历审计
该回顾性研究审查了瑞典和KPSC两个非典型股骨骨折队列,通过人工病历和药房记录核实双膦酸盐暴露。瑞典队列未发现额外暴露,无暴露比例保持22.1%;KPSC队列中29例初始无暴露者中20例发现既往暴露,无暴露比例从9.5%降至2.9%。误分类不能完全解释队列间差异。
要点
- 人工审查未改变瑞典队列的无暴露比例(22.1%)。
- KPSC队列无暴露比例从9.5%降至2.9%。
- 双膦酸盐暴露误分类存在但不足以解释队列间巨大差异。
核心结论
- 双膦酸盐暴露误分类确实存在,可显著影响报告的无暴露非典型股骨骨折比例,但不能完全解释不同研究间的宽幅差异,其他背景或方法学因素可能起作用。
研究设计与样本
- 回顾性研究,纳入瑞典队列172例(≥55岁,2008-2010年诊断AFF,其中38例无BP使用记录)和KPSC队列306例(≥50岁,2007-2017年诊断AFF,其中29例分类为BP初治),通过人工审查病历和药房数据核实BP暴露状态。
主要发现
- 瑞典队列人工审查未发现额外BP暴露,38/172例(22.1%)仍分类为BP初治。
- KPSC队列29例初始BP初治者中20例发现既往BP使用证据,BP初治比例从9.5%降至2.9%。
临床怎么用
- 在非典型股骨骨折研究中,应通过人工审查病历和药房记录核实双膦酸盐暴露,以减少误分类对无暴露比例的影响。
局限性
- 误分类不能完全解释队列间差异,其他背景或方法学因素仍需未来研究解决。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: We examined if inaccuracies in reported BP treatment in two large cohorts could explain the wide discrepancy observed between different patient cohorts with atypical femur fractures. Assessing BP treatment through manual review of medical and pharmacy records increased the discrepancy, indicating that other factors likely contribute to the observed variation. PURPOSE: Variation in results across fracture studies can stem from differences in study design, case definitions, data sources and healthcare settings, but in atypical femur fracture (AFF) studies, the reported proportion of AFF patients without bisphosphonate (BP) exposure shows an exceptionally wide variation. We aimed to evaluate whether misclassification of BP exposure could explain this variability and hypothesized that manual review of medical records would narrow differences between cohorts. METHODS: This retrospective study examined two population-based AFF cohorts: one from Sweden and one from Kaiser Permanente Southern California (KPSC). The Swedish cohort included 172 patients, aged ≥ 55 years with AFFs diagnosed between 2008 and 2010, of whom 38 had no recorded BP use. The KPSC cohort included 306 patients, aged ≥ 50 years with AFFs diagnosed between 2007 and 2017, of whom 29 were classified as BP-naïve. Manual review of medical records and pharmacy data was performed to verify BP exposure status. RESULTS: In the Swedish cohort, manual review did not identify any additional BP exposure, leaving 38 of 172 patients classified as BP-naïve (22.1%). In contrast, in the KPSC cohort, evidence of prior BP use was identified in 20 of 29 patients initially classified as BP-naïve, further reducing the proportion of BP-naïve AFF cases from 9.5 to 2.9%. CONCLUSION: Misclassification of BP exposure occurs and can substantially affect reported rates of BP-naïve AFF, but it does not fully explain the wide variation observed across studies. Additional contextual or methodological factors likely contribute and should be addressed in future AFF research.
引用
- Sand R, Adams AL, Gilfillan AD, et al. Manual chart review reveals bisphosphonate exposure misclassification in atypical femur fracture patients: auditing medical records in two international cohorts. Osteoporos Int. 2026. PMID: 42517882. doi:10.1007/s00198-026-08144-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。